FORT WORTH, Texas, Dec. 3 Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), a rapidly growing provider of specialty medical products, announced today an agreement with the Health Industry Representative Association (HIRA) to serve as a non-exclusive independent sales and marketing representative to market the company's core CellerateRx® product within the U.S.
HIRA will market and sell Wound Management Technologies' CellerateRx® throughout the U.S. CellerateRx®, is used in the management of pressure ulcers, traumatic wounds, diabetic ulcers, first and second degree burns, venous stasis ulcers, ulcers due to arterial insufficiency and superficial wounds. CellerateRx® targets a worldwide market in excess of several billion dollars.
"HIRA brings an additional avenue for serious market penetration to our sales organization," said Cathy Bradshaw, President of Wound Care Innovations, the division that markets CellerateRx®. "We continue to work to increase the size of our sales force and market share. The third quarter 2009 numbers show that our efforts are paying off; our next benchmark is to become profitable in 2010 and bring earnings to the bottom line as quickly as possible," stated WNDM CEO Scott Haire.
For Wound Management Technologies Shareholder Information please call 954-357-0614.
The Health Industry Representatives Association (HIRA) is a trade association of professionals in the healthcare industry. HIRA focuses on promoting the manufacturers' rep function within the health care industry. Its members are independent sales agencies located across the nation who offer manufacturers a professional, highly qualified sales force. Additionally, allied members are manufacturers who support the continuing use of independent sales agencies to market their products.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. (OTCBB-WNDM), with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida is a rapidly growing provider of specialty medical products and advanced biotechnology solutions. The Company is following the lead of NASDAQ Biotech Stock INDEX leaders such as Celgene (CELG) http://www.celgene.com, Geron (GERN) http://www.geron.com, and Human Genome Sciences (HGSI) http://www.hgsi.com by working to leverage its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering fields. WNDM also has an interest in Cancer Treatment. For more information on the Company please visit http://www.woundmanagementtechnologies.com or call our shareholder information department at 954-357-0614.
"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Further Information:
Shareholder Relations - Communications Ronnie Ambrose 954-357-0614
SOURCE Wound Management Technologies, Inc.